ANDA 201025, held by OneSource Specialty. Ampicillin Sodium.
As of Nov 21, 2026, ANDA 201025 (Ampicillin Sodium), held by OneSource Specialty, was first approved by FDA on Apr 9, 2014, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 9, 2014 | Original application | Approved | None posted |
| Ampicillin SodiumEQ 250MG BASE/VIAL · injectable;injection | Ampicillin Sodium | Discontinued |
| Ampicillin SodiumEQ 500MG BASE/VIAL · injectable;injection | Ampicillin Sodium | Discontinued |
| Ampicillin SodiumEQ 1GM BASE/VIAL · injectable;injection | Ampicillin Sodium | Rx |
| Ampicillin SodiumEQ 2GM BASE/VIAL · injectable;injection | Ampicillin Sodium | Rx |
| May 1, 2024 | Supplement 10Labeling · Standard review | Approved | None posted |
| Mar 14, 2018 | Supplement 1Labeling · Standard review | Approved | None posted |
| Mar 14, 2018 | Supplement 3Labeling · Standard review | Approved | None posted |
| Apr 9, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters